Genentech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH, and what generic alternatives to GENENTECH drugs are available?
GENENTECH has nine approved drugs.
There are fifty-six US patents protecting GENENTECH drugs.
There are eight hundred and forty-three patent family members on GENENTECH drugs in fifty-three countries and eighty-six supplementary protection certificates in nineteen countries.
Summary for Genentech
| International Patents: | 843 |
| US Patents: | 56 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 9 |
| Patent Litigation for Genentech: | See patent lawsuits for Genentech |
| PTAB Cases with Genentech as patent owner: | See PTAB cases with Genentech as patent owner |
Drugs and US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | 7,767,700 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | 9,085,565 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 8,420,674 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,592,462 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | 8,383,150 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 7,816,383 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for Genentech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 591443 | ⤷ Try a Trial |
| Russian Federation | 2014151565 | ⤷ Try a Trial |
| Japan | 7154271 | ⤷ Try a Trial |
| Japan | 2015232045 | ⤷ Try a Trial |
| Hong Kong | 1176002 | ⤷ Try a Trial |
| Taiwan | I804919 | ⤷ Try a Trial |
| Japan | 2015531763 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1789390 | CR 2013 00050 | Denmark | ⤷ Try a Trial | PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530 |
| 2176231 | 122020000081 | Germany | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB ODER ISOMERE, TAUTOMERE ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1460 20200731 |
| 3107541 | 132021000000107 | Italy | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB IN TUTTE LE SUE FORME PROTETTE DAL BREVETTO DI BASE: ENTRECTINIB O SUOI ISOMERI, TAUTOMERI O SALI FARMACEUTICAMENTE ACCETTABILI(ROZLYTREK ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1460, 20200803 |
| 2176231 | 2020C/551 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB OF ISOMEREN, TAUTOMEREN OF FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1460 20200803 |
| 2620436 | PA2021505 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: BALOKSAVIRO MARBOKSILAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/20/1500 20210107 |
| 1934174 | 22/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB ALS EIN EINZELNES STEREOISOMER ODER ALS EINE MISCHUNG VON STEREOISOMEREN DAVON, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE UND SOLVATE, INSBESONDERE COBIMETINIB HEMIFUMARAT; REGISTRATION NO/DATE: EU/1/15/1048 (MITTEILUNG) 20151124 |
| 3143025 | 301128 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RISDIPLAM OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1531 20210329 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
